Clinical efficacy of hepatic arterial infusion chemotherapy combined with transhepatic arterial embolization plus lenvatinib and tislelizumab or transarterial chemoembolization combined with lenvatinib plus tislelizumab in the treatment of advanced h
The quadruple combination of HAIC, TAE, lenvatinib, and tislelizumab in the treatment of advanced HCC has a better prognosis than the triple combination of TACE in combination with lenvatinib and tislelizumab, with tolerant safety.
Authors
- Hai Hui Huang (ORCID: https://orcid.org/0000-0001-7430-0119)
- Zha Peng (ORCID: https://orcid.org/0000-0003-3488-5911)
- Boyu Chen (ORCID: https://orcid.org/0000-0002-1422-713X)
- Zhuangrong Zhu
- Yaqiong Wang (ORCID: https://orcid.org/0000-0002-7041-102X)
- Wei Yang (ORCID: https://orcid.org/0000-0003-0198-1632)
- Chengyi He (ORCID: https://orcid.org/0000-0002-7063-3802)
Institutions
- Guangxi Medical University (CN)
- Dongguan People’s Hospital (CN)
- First Affiliated Hospital of GuangXi Medical University (CN)
- The Second Nanning People's Hospital (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-12-02
- DOI
- https://doi.org/10.3389/fonc.2025.1665348
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China